Prix Alterity Therapeutics Limited (PRNAF)

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The firm is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.